News

TherapeuticsMD, Inc. an innovative, leading women’s healthcare company, today announced that it has entered into definitive agreements to license its products to an affiliate of Mayne…
Read More...

Incyte and CMS Aesthetics, a dermatology medical aesthetic company and subsidiary of CMS announced that the companies have entered into a Collaboration and License Agreement for the…
Read More...

AbCellera and Rallybio Corporation announced that they have entered into a strategic alliance to discover, develop, and commercialize novel antibody-based therapeutics for rare…
Read More...

Hoffmann-La Roche Limited (Roche Canada) announced that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA  IV (tocilizumab for…
Read More...

BioNTech SE and Ryvu Therapeutics S.A., a clinical-stage company developing oncology therapeutics announced that the companies have entered into a multi-target research collaboration…
Read More...

Biocon Biologics Ltd., a subsidiary of Biocon Ltd. announced today that it has successfully completed its multi-billion-dollar (USD) acquisition of the global biosimilars business of…
Read More...

Liminatus Pharma LLC (“Liminatus”), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp (“Iris”), a publicly traded…
Read More...

iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with…
Read More...

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the…
Read More...

Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic…
Read More...

argenx SE announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of…
Read More...

Kintara Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of…
Read More...

Aldeyra Therapeutics, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new…
Read More...

Clinigen Limited has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add…
Read More...

Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with …
Read More...

Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies…
Read More...

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...

ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral…
Read More...

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop…
Read More...